文献速递心力衰竭与心肌病

沙库巴曲/缬沙坦对心力衰竭患者体力与社交活动受限的影响:PARADIGM-HF试验二次分析

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该研究为PARADIGM-HF试验的二次分析,纳入8399例NYHA II-IV级且LVEF≤40%的心衰患者,随机接受沙库巴曲/缬沙坦或依那普利治疗。结果显示,在8个月和36个月时,沙库巴曲/缬沙坦组在多数KCCQ体力与社交活动项目上较依那普利组有显著改善,以家务和性关系改善最明显。

要点

  • 沙库巴曲/缬沙坦较依那普利显著改善多数KCCQ体力与社交活动评分。
  • 家务和性关系改善幅度最大,且持续至36个月。
  • 在降低心血管死亡、全因死亡和心衰住院风险之外,可改善常见活动受限。

核心结论

  • 在射血分数降低的心衰患者中,沙库巴曲/缬沙坦较依那普利显著改善几乎所有KCCQ体力与社交活动项目,家务和性关系改善最大。

研究设计与样本

  • 干预为沙库巴曲/缬沙坦200 mg每日两次或依那普利10 mg每日两次。

主要发现

  • 基线时8399例中7618例(90.7%)完成初始KCCQ评估,平均(SD)年龄64(11)岁,男性5987例(78.6%),女性1631例(21.4%)。
  • 基线时患者报告受限最严重的项目为慢跑和性关系。
  • 8个月时沙库巴曲/缬沙坦组在多数体力与社交活动上的校正变化评分显著优于依那普利组,并持续至36个月。
  • 家务的校正变化评分差异为2.35(95%CI 1.19-3.50,P<.001),性关系为2.72(95%CI 0.97-4.46,P=.002)。
  • 36个月总体变化评分差异:家务1.69(95%CI 0.78-2.60,P<.001),性关系2.36(95%CI 1.01-3.71,P=.001)。

临床怎么用

  • 对NYHA II-IV级且LVEF≤40%的心衰患者,沙库巴曲/缬沙坦可在降低心血管死亡、全因死亡和心衰住院风险的同时改善常见活动受限。
  • 临床评估可关注患者家务和性关系等体力与社交活动受限的改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Health-related quality of life (HRQL) of patients with heart failure is markedly reduced compared with that in patients with other chronic diseases, demonstrating substantial limitations in physical and social activities. In the Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, sacubitril/valsartan improved overall HRQL compared with enalapril, as determined by the Kansas City Cardiomyopathy Questionnaire (KCCQ). OBJECTIVE: To examine the effects of sacubitril/valsartan on physical and social activities. DESIGN, SETTING, AND PARTICIPANTS: The PARADIGM-HF trial was a randomized, double-blind, active treatment-controlled clinical trial performed from December 8, 2009, to March 31, 2014, in 8399 patients with New York Heart Association class II to IV disease and a left ventricular ejection fraction of 40% or less at 1043 centers in 38 countries. Data analysis was performed from August 1, 2017, to December 25, 2017. INTERVENTIONS: Sacubitril/valsartan, 200 mg twice daily, or enalapril, 10 mg twice daily. MAIN OUTCOMES AND MEASURES: Patients completed HRQL assessments using the KCCQ at randomization, 4-month, 8-month, and annual visits. The effect of sacubitril/valsartan on components of the physical and social limitation sections of the KCCQ at 8 months and longitudinally and related biomarkers and clinical outcomes were studied. RESULTS: At baseline, 7618 of 8399 patients (90.7%) (mean [SD] age, 64 [11] years; 5987 [78.6%] male and 1631 [21.4%] female) completed the initial KCCQ assessment. Patients reported the greatest limitations at baseline in jogging and sexual relationships. Patients receiving sacubitril/valsartan had significantly better adjusted change scores in most physical and social activities at 8 months and during 36 months compared with those receiving enalapril. The largest improvement over enalapril was in household chores (adjusted change score difference, 2.35; 95% CI, 1.19-3.50; P < .001) and sexual relationships (adjusted change score difference, 2.72; 95% CI, 0.97-4.46; P = .002); both persisted through 36 months (overall change score difference, 1.69 [95% CI, 0.78-2.60], P < .001; and 2.36 [95% CI, 1.01-3.71], P = .001, respectively). CONCLUSIONS AND RELEVANCE: In patients with heart failure with reduced ejection fraction, sacubitril/valsartan significantly improved nearly all KCCQ physical and social activities compared with enalapril, with the largest responses in household chores and sexual relationships. In addition to reduced likelihood of cardiovascular death, all-cause mortality, and heart failure hospitalization, sacubitril/valsartan may improve limitations in common activities in these patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01035255.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Chandra A, Lewis EF, Claggett BL, et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018. PMID: 29617523. doi:10.1001/jamacardio.2018.0398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。